Recent clinical reports have suggested that the cyclooxygenase-2 inhibitor, lumiracoxib (Prexige), may cause a rare but serious hepatotoxicity in patients. In view of the close structural resemblance between lumiracoxib and diclofenac, a widely used nonsteroidal anti-inflammatory drug whose use also has been associated with rare cases of liver injury, it is possible that the toxicity of the two agents may share a common mechanism. Because it is believed that chemically reactive metabolites may play a role as mediators of diclofenac-mediated hepatotoxicity, the present in vitro study was carried out to test the hypothesis that lumiracoxib also undergoes metabolic activation when incubated with liver microsomal preparations and hepatocytes from rats and humans. By means of liquid chromatography tandem mass spectrometry and nuclear magnetic resonance spectrometry techniques, two previously unknown N-acetylcysteine (NAC) conjugates were identified, namely, 3-NAC-4-hydroxy lumiracoxib (M1) and 4-hydroxy-6-NAC-desfluoro lumiracoxib (M2), the structures of which reveal the intermediacy of an electrophilic quinone imine species. Based on the results of studies with immunoinhibitory antibodies, it was demonstrated that the formation of M1 and M2 in human liver microsomes was catalyzed by cytochrome P450 (P450) 2C9. These findings demonstrate that lumiracoxib is subject to P450-mediated bioactivation in both rat and human liver preparations, leading to the formation of a reactive intermediate analogous to species generated during the metabolism of diclofenac.
Lumiracoxib [2-(2Ј-chloro-6Ј-fluorophenyl)-amino-5-methylbenzeneacetic acid] (Prexige; Novartis, Basel, Switzerland) ( Fig. 1 ) is a selective cyclooxygenase-2 inhibitor approved in over 50 countries worldwide for the treatment of osteoarthritis and acute pain (Bannwarth and Berenbaum, 2007; Buvanendran and Barkin, 2007) . Recently, concerns have been raised over the clinical safety of lumiracoxib after reports of rare but serious liver reactions to the drug. Thus, eight cases of lumiracoxib-associated hepatotoxicity were reported in Australia, resulting in two deaths and two liver transplants. In light of these adverse reactions, the Australian Therapeutic Goods Administration cancelled the registration of the drug in that country in August, 2007 , and the higher doses (200 and 400 mg) of lumiracoxib now have been removed from the New Zealand market by the Medicines and Medical Devices Safety Authority (http://www.novartis.com.au/ Prexige%20press%20release%2011%20August.pdf; http://www.tga.
gov.au/media/2007/070811-lumiracoxib.htm; and http://www.medsafe. govt.nz/hot/media/2007/prexige.asp).
From a structural standpoint, lumiracoxib is a close relative of diclofenac, a drug itself known to induce a rare but severe hepatotoxicity in exposed patients. Although the precise mechanism of diclofenac-mediated hepatotoxicity remains elusive, it has been proposed that chemically reactive metabolites of the drug may play a causative role (Boelsterli, 2003; Tang, 2003) . Thus, diclofenac is known to undergo cytochrome P450 (P450)-catalyzed hydroxylation at the 4Ј-and 5-positions, the products of which may be further oxidized to reactive quinone imine intermediates that have been characterized indirectly as their corresponding glutathione adducts (Tang, 2003) . In the case of lumiracoxib, a methyl substituent occupies the 5-position, whereas the dichloroaniline moiety of diclofenac has been replaced by a fluorochloroaniline ring system (Fig. 1 ). Despite these structural changes, the potential remains for metabolic activation of lumiracoxib to a quinone imine to occur through hydroxylation at the exposed 4Ј-position. The present investigation was designed, therefore, to test the hypothesis that lumiracoxib undergoes P450-mediated metabolism to a reactive quinone imine intermediate when incubated with liver preparations from rat and human subjects and that the putative electrophilic species may be captured as a thioether adduct(s) with the model nucleophile N-acetylcysteine (NAC). The results of this preliminary study confirm that lumiracoxib does undergo such bioactivation in vitro.
Materials and Methods
Materials. Lumiracoxib was prepared according to methods described in the international patent application WO 01/23346. Rat and human liver microsomes and monoclonal inhibitory anti-CYP2C9 and anti-CYP3A4 antibodies were prepared at Merck Research Laboratories (West Point, PA) (Shou et al., 2000) . Cryopreserved human hepatocytes from three donors and InVitroGRO Hepatocyte Media were obtained from In Vitro Technologies (Baltimore, MD). All other reagents were from commercial sources.
Analytical Methods. LC-MS/MS was carried out on a Finnigan LCQ Deca XP Plus ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) with IonSpray in the positive ion detection mode. Highperformance liquid chromatography was performed on a Phenomenex (Torrance, CA) Synergi Hydro-RP column (4.6 ϫ 50 mm, 4 m) operated at a flow rate of 1 ml/min. The mobile phase consisted of aqueous acetonitrile containing 0.05% acetic acid and 1 mM ammonium acetate and was programmed via a linear increase of acetonitrile content from 5 to 76% over a period of 30 min.
1 H NMR spectra were recorded on a Varian (Palo Alto, CA) Inova 600 spectrometer operated at 600 MHz.
In Vitro Metabolism. Incubations of lumiracoxib (50 M) with rat or human liver microsomes (1 mg protein/ml) were performed in the presence of NADPH (1 mM) and NAC (5 mM) at 37°C for 60 min. The incubation medium was phosphate buffer (100 mM, pH 7.4) containing EDTA (1 mM), and the volume was 1 ml. Incubations in immunoinhibitory studies were performed in a similar manner, except that the anti-CYP2C9 or 3A4 antibody was preincubated with human liver microsomes for 15 min at room temperature before initiation of lumiracoxib metabolism. The reaction mixture was acidified to pH 2 to 3 with 10% aqueous trifluoroacetic acid and extracted with an Oasis HLB extraction cartridge (Waters Co., Milford, MA).
Incubations of lumiracoxib (50 M) with human hepatocytes (1 ϫ 10 6 cells/ml) were performed in the presence of NAC (5 mM) at 37°C for 60 min. The incubation medium was InVitroGRO Hepatocyte Media, and the volume was 5 ml. After acidification to pH 2 to 3 with 10% aqueous trifluoroacetic acid, the cells were lysed via sonication, and the mixture was extracted with an Oasis HLB extraction cartridge. The resulting samples were analyzed by LC-MS/MS. Samples from liver microsomal incubations (200 ml incubation) were further purified by highperformance liquid chromatography for NMR analysis.
Results and Discussion
Two NAC conjugates, M1 and M2, were identified by LC-MS/MS analysis after incubations of lumiracoxib with rat and human liver Fig. 2A) . Further CID of the m/z 453 ion (Fig. 2B) afforded fragment ions at m/z 435 (loss of water), 411 (loss of ketene), 407 (loss of formic acid), and 365 (combined losses of ketene and formic acid). The weak fragment ions at m/z 342 ( Fig. 2A) and 324 (Fig. 2, A and B ; loss of water from the m/z 342 ion) may be ascribed to cleavage of the CH 2 -S bond with charge retention on the aromatic ring.
M2 exhibited an MH ϩ ion at m/z 453/455 (chlorine isotopes), suggesting that this metabolite may correspond to the product of addition of NAC to an intermediate that had undergone oxidation and defluorination. CID of the MH ϩ ion at m/z 453 produced a fragment at m/z 435, resulting from loss of the elements of water (Fig. 3A) . Further CID of the ion at m/z 435 (Fig. 3B ) afforded ions at m/z 417 (loss of water), 393 (loss of ketene), 389 (loss of formic acid), and 347 (loss of formic acid from the m/z 393 ion or loss of ketene from the m/z 389 ion). The fragment ion at m/z 306 probably is due to cleavage of the thioether moiety, similar to that observed with M1. 1 H NMR analysis of M1 isolated from liver microsomal incubations indicated that only one proton (Fig. 4, d ) remained on the halogenated aniline with ortho-coupling to the fluorine. The NAC substituent therefore is assigned to the position para to the fluorine (Fig. 4) . The 1 H NMR spectrum of M2 exhibited two meta-oriented protons (Fig. 5, d and e) without fluorine coupling on the halogenated aniline ring. In addition, the cysteine ␤-protons displayed a nuclear Overhauser effect only to one of the aromatic protons (Fig. 5, d ), suggesting that NAC substitution is at the position ortho to the amino group. On this basis, M1 and M2 are assigned as 3Ј-NAC-4Ј-hydroxy lumiracoxib and 4Ј-hydroxy-6Ј-NAC-desfluoro lumiracoxib, respectively.
Formation of M1 and M2 in human liver microsomal incubations was inhibited by the monoclonal anti-CYP2C9 antibody (ϳ100 and 75%, respectively) but was not affected by the anti-CYP3A4 antibody (data not shown). This finding is consistent with data reported previously that lumiracoxib metabolism in man is catalyzed primarily by CYP2C9 (Mangold et al., 2004) .
The detection of M1 and M2 in incubations of lumiracoxib with rat and human liver microsomal preparations fortified with NAC suggests that the drug is subject to metabolic activation in these systems (Tang and Miller, 2004) . Thus, lumiracoxib undergoes hydroxylation to afford 4Ј-hydroxylumiracoxib, further oxidation of which leads to the formation of a putative quinone imine intermediate (Fig. 6 ). These reactions are catalyzed by CYP2C9 in human liver microsomes. The quinone imine intermediate then is captured by NAC to afford the thioether conjugates M1 and M2. Formation of M2 is of mechanistic interest as it involves a selective displacement of fluorine (as opposed to chlorine) by NAC. A plausible explanation for this observation is that, compared with chlorine, the smaller size and stronger electron-withdrawing effect of fluorine renders the fluorinated carbon atom a preferred target for attack by nucleophiles such as NAC, and the overall process is dictated by the kinetics of the initial nucleophilic addition step as opposed to the subsequent halide elimination. Interestingly, in the case of diclofenac, which possesses a dichloroaniline moiety instead of a fluorochloroaniline ring system, a glutathione adduct resulting from thiol substitution of chlorine was detected in human liver microsomal incubations (Yu et al., 2005) .
The identification of the NAC conjugates M1 and M2 in human hepatocyte suspensions suggests that lumiracoxib metabolism to reactive quinone imine intermediate(s) may take place in patients. In addition to forming thiol adducts, quinone imines are known to be capable of covalently modifying cellular proteins and have been implicated in a number of drug-related adverse effects (Guengerich and MacDonald, 2007; Tang, 2007) . It should be noted that neither M1 nor M2 (nor other thioether conjugates) was detected in a single-dose study of lumiracoxib metabolism in four healthy male subjects (Mangold et al., 2004) . However, in light of the recent withdrawal of lumiracoxib from the Australian market and its restricted use in New Zealand, further studies of the metabolic fate of the drug in humans may be warranted to better understand the relationship between lumiracoxib metabolism and its adverse hepatic effects. 
